Inhibition of human cytomegalovirus DNA maturation by a benzimidazole ribonucleoside is mediated through the UL89 gene product
about
Novel class of thiourea compounds that inhibit herpes simplex virus type 1 DNA cleavage and encapsidation: resistance maps to the UL6 gene.Letermovir and inhibitors of the terminase complex: a promising new class of investigational antiviral drugs against human cytomegalovirusCurrent and potential treatments for ubiquitous but neglected herpesvirus infectionsStructure and inhibition of herpesvirus DNA packaging terminase nuclease domainInhibition of Epstein-Barr virus replication by a benzimidazole L-riboside: novel antiviral mechanism of 5, 6-dichloro-2-(isopropylamino)-1-beta-L-ribofuranosyl-1H-benzimidazole.Phosphorylation of beta-D-ribosylbenzimidazoles is not required for activity against human cytomegalovirusA novel nonnucleoside inhibitor specifically targets cytomegalovirus DNA maturation via the UL89 and UL56 gene products.Susceptibilities of human cytomegalovirus clinical isolates to BAY38-4766, BAY43-9695, and ganciclovirInhibition of ganciclovir-susceptible and -resistant human cytomegalovirus clinical isolates by the benzimidazole L-riboside 1263W94Resistance of human cytomegalovirus to benzimidazole ribonucleosides maps to two open reading frames: UL89 and UL56Role of the UL25 protein in herpes simplex virus DNA encapsidationHerpes simplex virus DNA cleavage and packaging proteins associate with the procapsid prior to its maturation.Resistance of human cytomegalovirus to the benzimidazole L-ribonucleoside maribavir maps to UL27Human cytomegalovirus UL97 Kinase is required for the normal intranuclear distribution of pp65 and virion morphogenesisHtrA2/Omi terminates cytomegalovirus infection and is controlled by the viral mitochondrial inhibitor of apoptosis (vMIA)Impact of 2-bromo-5,6-dichloro-1-beta-D-ribofuranosyl benzimidazole riboside and inhibitors of DNA, RNA, and protein synthesis on human cytomegalovirus genome maturation.Distinct and separate roles for herpesvirus-conserved UL97 kinase in cytomegalovirus DNA synthesis and encapsidation.Identification of small molecule compounds that selectively inhibit varicella-zoster virus replicationIsolation and characterization of the herpes simplex virus 1 terminase complex.Human cytomegalovirus UL97 kinase and nonkinase functions mediate viral cytoplasmic secondary envelopment.Human cytomegalovirus resistance to deoxyribosylindole nucleosides maps to a transversion mutation in the terminase subunit-encoding gene UL89.In vitro activities of benzimidazole D- and L-ribonucleosides against herpesviruses.Rhesus cytomegalovirus is similar to human cytomegalovirus in susceptibility to benzimidazole nucleosidesThe Varicella-zoster virus ORF54 gene product encodes the capsid portal protein, pORF54.Orthopoxvirus targets for the development of antiviral therapies.Intermolecular Complementation between Two Varicella-Zoster Virus pORF30 Terminase Domains Essential for DNA Encapsidation.The human cytomegalovirus UL51 protein is essential for viral genome cleavage-packaging and interacts with the terminase subunits pUL56 and pUL89.Control of cytoplasmic maturation events by cytomegalovirus tegument protein pp150.Role of a mutation in human cytomegalovirus gene UL104 in resistance to benzimidazole ribonucleosides.Dramatic effects of 2-bromo-5,6-dichloro-1-beta-D-ribofuranosyl benzimidazole riboside on the genome structure, packaging, and egress of guinea pig cytomegalovirus.The Varicella-zoster virus DNA encapsidation genes: Identification and characterization of the putative terminase subunits.Mutagenesis of the murine cytomegalovirus M56 terminase gene.Cytomegalovirus vaccine strain towne-derived dense bodies induce broad cellular immune responses and neutralizing antibodies that prevent infection of fibroblasts and epithelial cells.Characterization of the Varicella-zoster virus ORF25 gene product: pORF25 interacts with multiple DNA encapsidation proteins.The non-nucleoside antiviral, BAY 38-4766, protects against cytomegalovirus (CMV) disease and mortality in immunocompromised guinea pigsProduction of Cytomegalovirus Dense Bodies by Scalable Bioprocess Methods Maintains Immunogenicity and Improves Neutralizing Antibody Titers.Distribution and effects of amino acid changes in drug-resistant α and β herpesviruses DNA polymeraseInhibition of human cytomegalovirus replication by benzimidazole nucleosides involves three distinct mechanisms.Epstein-Barr virus BALF3 has nuclease activity and mediates mature virion production during the lytic cycle.Activities of benzimidazole D- and L-ribonucleosides in animal models of cytomegalovirus infections.
P2860
Q24515073-D1BFDD40-BC58-4B1D-8C94-1B9DA8DA6C45Q26783282-5F546C16-07A3-4C2F-8BC8-1FB8E51A6FF3Q27023452-1ABDED8F-528B-46E0-AAE9-713D981C328EQ27664231-30D2FC97-7C7A-48B7-9732-A64D76EBC5F8Q28343493-D17CD657-2707-4DBA-BEF7-4FF8CED4FB28Q28345180-8A81B112-58C2-411A-BD4F-AFCFF8FF979EQ28348812-52FE8A46-72B9-4857-B8DD-6F90AC09D598Q28353356-803BA8D9-82A0-479B-9B58-EF6BF53725CFQ28362995-CECD2888-B984-4266-943A-5C7940E47DB3Q28379493-2A9EFF89-B35A-4B4A-9236-F89C95DA1A31Q30439328-62C484F2-0DB1-4559-B35F-44B1B4535174Q30453463-3FF6EE81-58FF-491C-9D27-07FDB74A05DCQ31011523-B4924AAF-D9C5-4019-A371-369B0DA7BBB2Q33227757-18A45965-B9BE-4B9D-A6DB-165F2439C79DQ33366478-DC084ACA-3663-4276-88F4-FC23D3573620Q33930394-601C1D77-01D9-4431-84F1-6B368253E0FAQ34109911-F25F4DC7-30AA-4B39-9A58-D45CBEE1A261Q34471804-42BC8A9A-470D-4440-9938-5942B8CC862FQ34656890-DC1A4966-762A-435A-8B98-6956B8933BD8Q34742654-4AE6EBA8-F0DA-4434-B41A-173A3B324382Q34922240-C9B35FE1-F8CD-41B3-BBB0-59871D208B15Q35103227-135FC72B-3725-451D-8347-0E34087B8CE1Q35124909-770BE589-4497-4EA0-8ADE-1641B35CD888Q35992020-6C290A1D-F404-4BC2-AF78-4E90DCF39D04Q36074391-1BDEF696-3D5E-4BCF-AA06-70C09D5068F0Q36080899-26A0341B-DF80-4FAB-8561-49F67C1DC3DEQ36559969-AC3A5655-564E-4EBF-B4BB-1A8B7A82BE42Q36898866-5B16AA8E-376B-49AF-AA24-20F918667741Q36944070-BE312465-6EE2-480D-A006-1DE1BDB8B515Q36960023-DE897B80-3301-40BC-8E2A-1E9A47B4AA01Q37158547-9EF1EDB5-C168-478F-BC28-71C9A770D450Q37165587-F71FE808-4DDE-40FC-91E3-283A388B2C29Q37252609-378209FC-3611-42F0-B238-51860F256FF8Q37330959-672A8A5C-4F69-4F6B-842A-5C076013E6EFQ37401583-53678473-A725-4584-AEFF-F9335C64AFE5Q37409233-178FB3A3-E566-4262-997D-3ED024B80F02Q37523020-9C2ABCF8-6B80-4F07-84D3-0B9D007B56C9Q37568962-DF7841B5-4AE0-4944-8647-5AA4C78D3ECEQ37714026-CC8AC470-60A1-47D6-B07C-90FDADFA5663Q37734561-962F8766-C061-46B8-B2CF-B860C82F402A
P2860
Inhibition of human cytomegalovirus DNA maturation by a benzimidazole ribonucleoside is mediated through the UL89 gene product
description
1998 nî lūn-bûn
@nan
1998 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
1998 թվականի հունվարին հրատարակված գիտական հոդված
@hy
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
name
Inhibition of human cytomegalo ...... through the UL89 gene product
@ast
Inhibition of human cytomegalo ...... through the UL89 gene product
@en
Inhibition of human cytomegalo ...... through the UL89 gene product
@nl
type
label
Inhibition of human cytomegalo ...... through the UL89 gene product
@ast
Inhibition of human cytomegalo ...... through the UL89 gene product
@en
Inhibition of human cytomegalo ...... through the UL89 gene product
@nl
prefLabel
Inhibition of human cytomegalo ...... through the UL89 gene product
@ast
Inhibition of human cytomegalo ...... through the UL89 gene product
@en
Inhibition of human cytomegalo ...... through the UL89 gene product
@nl
P2093
P2860
P1433
P1476
Inhibition of human cytomegalo ...... through the UL89 gene product
@en
P2093
L B Townsend
M L Hemphill
M R Underwood
R J Harvey
S C Stanat
P2860
P304
P407
P577
1998-01-01T00:00:00Z